Riskpilot← Back to searchSign inGet full accessSynamics Therapeutics ApS
APSActiveCVR 44258048Fruebjergvej 3Research and experimental development on natural sciences and engineering · NACE 7210Est. 20235 employees
Revenue 2024
DKK -1,7M
EBITDA margin
116.9%
Equity ratio
13.3%
Financial strength
Net profit 2024
DKK -1,6M
5 employees
| Revenue | DKK -1,7M | — |
| EBITDA | DKK -2M | — |
| Net profit | DKK -1,6M | — |
| Total assets | DKK 3,5M | +8774% |
| Equity | DKK 473K | +1082% |
| Employees | 5 | — |
Legal name
Synamics Therapeutics ApS
CVR number
44258048
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
24. august 2023
Share capital
DKK 50.735
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør sammen med bestyrelsesformanden eller af den samlede bestyrelse
Company purpose
Selskabets formål er at fremskynde opdagelsen af lægemidler gennem udvikling af kunstig intelligens og maskinlæring og at identificere nye forbindelser og mål
Address
Fruebjergvej 3
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2023 | 2024 |
|---|---|---|
| Revenue | — | -1.695 |
| Staff expenses | -0 | -287 |
| EBITDA | 0 | -1.982 |
| Depreciation & amort. | -0 | -3 |
| EBIT | 0 | -1.985 |
| Net financials | 0 | -11 |
| Profit before tax | 0 | -1.996 |
| Tax | -0 | -442 |
| Net profit | 0 | -1.554 |
| Item | 2023 | 2024 |
|---|---|---|
| Total assets | 40 | 3.550 |
| Equity | 40 | 473 |
| Long-term debt | 0 | 0 |
| Short-term debt | 0 | 2.960 |
| Total debt | 0 | 2.960 |
EBITDA margin
-198197200.0%
This company
15.8%
Market median
-1254412758% vs market
20232024
Equity ratio
13.3%
This company
38.2%
Market median
-65% vs market
20232024
Return on equity
-328.8%
This company
18.4%
Market median
-1887% vs market
20232024
Net profit margin
-155427400.0%
This company
8.1%
Market median
-1918856890% vs market
20232024
Asset turnover
-0.48×
This company
1.12×
Market median
-143% vs market
20232024
Debt / equity
6.51×
This company
0.62×
Market median
-950% vs market
20232024
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
CH Founder | Founder | 2023 |
VZ Management | Management | 2023 |
HT Founder | Founder | 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2023 | |
| Board of Directors | 2023 | |
| Board of Directors | 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2025 | |
| Company | 10–14.99% | 10–14.99% | 2024 | |
| Individual | 10–14.99% | 10–14.99% | 2024 | |
| Individual | 25–33.32% | 25–33.32% | 2024 | |
| Company | 10–14.99% | 10–14.99% | 2024 | |
| Company | 10–14.99% | 10–14.99% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Synamics Therapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Continuum Holdings Inc. | Founder | 0 companies |
| Violet Zahedi | Management | 0 companies |
| Helder Takashi Imoto Nakaya | Founder | 0 companies |
| Aaron Daniel Capar | Chairman | 0 companies |
| Albert Jelke Kooistra | Board of Directors | 0 companies |
| Per Falholt | Board of Directors | 0 companies |